- Home
- GLRE vs ALMS Comparison
GLRE vs ALMS Comparison
Compare GLRE & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- ALMS
- Stock Information
- Founded
- GLRE 2004
- ALMS 2021
- Country
- GLRE Cayman Islands
- ALMS United States
- Employees
- GLRE N/A
- ALMS N/A
- Industry
- GLRE Property-Casualty Insurers
- ALMS
- Sector
- GLRE Finance
- ALMS
- Exchange
- GLRE Nasdaq
- ALMS NYSE
- Market Cap
- GLRE 469.0M
- ALMS 402.6M
- IPO Year
- GLRE 2007
- ALMS 2024
- Fundamental
- Price
- GLRE $13.45
- ALMS $5.00
- Analyst Decision
- GLRE
- ALMS Strong Buy
- Analyst Count
- GLRE 0
- ALMS 7
- Target Price
- GLRE N/A
- ALMS $28.17
- AVG Volume (30 Days)
- GLRE 126.8K
- ALMS 1.6M
- Earning Date
- GLRE 05-07-2025
- ALMS 05-15-2025
- Dividend Yield
- GLRE N/A
- ALMS N/A
- EPS Growth
- GLRE N/A
- ALMS N/A
- EPS
- GLRE 1.24
- ALMS N/A
- Revenue
- GLRE $701,632,000.00
- ALMS N/A
- Revenue This Year
- GLRE N/A
- ALMS N/A
- Revenue Next Year
- GLRE N/A
- ALMS N/A
- P/E Ratio
- GLRE $10.85
- ALMS N/A
- Revenue Growth
- GLRE 7.08
- ALMS N/A
- 52 Week Low
- GLRE $11.93
- ALMS $3.18
- 52 Week High
- GLRE $15.82
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- GLRE 52.53
- ALMS N/A
- Support Level
- GLRE $12.88
- ALMS N/A
- Resistance Level
- GLRE $13.33
- ALMS N/A
- Average True Range (ATR)
- GLRE 0.51
- ALMS 0.00
- MACD
- GLRE 0.03
- ALMS 0.00
- Stochastic Oscillator
- GLRE 71.58
- ALMS 0.00
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.